Rocket Pharmaceuticals, Inc., a leading U.S.-based multi-platform gene therapy company, and the Stanford University School of Medicine today announced a strategic collaboration to support the advancement of Fanconi Anemia and Pyruvate Kinase Deficiency gene therapy research.
↧
